Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems.
Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35
kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with
improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that
bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to
counteract metabolically favourable incretins. In view of the recent studies, it may be that
GIP is really the anti-incretin behind this hypothesis.
The current study is conducted to investigate the vasoactive roles of the GIP. The
investigators aim to show that GIP is the major contributor to the blood flow and tissue
blood volume observed in postprandial state.
Phase:
Phase 1
Details
Lead Sponsor:
Turku University Hospital
Collaborators:
Academy of Finland Lund University Sigrid Juselius Foundation